Neoadjuvant chemotherapy and radical cystectomy in patients with bladder cancer

Cover Page

Cite item

Full Text

Abstract

Background. Bladder cancer is the ninth most common malignant neoplasm worldwide. Hidden metastases at the time of diagnosis are the main reason muscle-invasive bladder cancer has poor prognosis. Even after radical cystectomy, muscleinvasive bladder cancer mostly progresses within 2 years with a recurrence rate of over 50 %. At stages II–IV of the disease, drug treatment is indicated before radical cystectomy. The main goal of neoadjuvant chemotherapy is to affect micrometastases, which may be present at the beginning of disease development. The response to ongoing chemotherapy can serve as a predictor of long-term survival.

Aim. To increase effectiveness of bladder cancer treatment.

Materials and methods. A total of 231 patients with bladder cancer were included in the study. The main contingent consisted of men over 60 years old with locally advanced tumors at stage Т2–Т4. Drug therapy was carried out in neoadjuvant mode before surgical treatment. Standard regimens were used: cisplatin + gemcitabine and MVAC (methotrexate, vinblastine, adriamycin, cisplatin). After four courses of neoadjuvant chemotherapy, the results were evaluated. With complete normalization of a patient’s condition, the issue of surgical treatment – radical cystectomy with one of the types of urinary diversion – was decided.

Results and conclusion. The follow-up period for patients after treatment was 62 months. In patients who underwent neoadjuvant chemotherapy, the median overall survival was 44.9 months, in patients without neoadjuvant treatment – 36.8 months with improvement in recurrence-free survival from 32.5 to 39.8 months (p = 0.08). Overall survival after neoadjuvant chemotherapy improved by 8.1 months (p = 0.09).

About the authors

O. B. Karyakin

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: Karyakin@mrrc.obninsk.ru
ORCID iD: 0000-0002-6112-2840

Oleg Borisovich Karyakin

4 Koroleva St., Obninsk 249031

Russian Federation

N. V. Vorobyov

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-5597-9533

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

I. N. Zaborskiy

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-5988-8268

4 Koroleva St., Obninsk 249031

Russian Federation

A. G. Muradyan

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-6601-6289

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

K. N. Safiullin

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-3029-9213

4 Koroleva St., Obninsk 249031

Russian Federation

I. A. Taraki

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-1870-3607

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

G. A. Demyashkin

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-8447-2600

4 Koroleva St., Obninsk 249031

Russian Federation

S. A. Ivanov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-7689-6032

4 Koroleva St., Obninsk 249031

Russian Federation

A. D. Kaprin

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-8784-8415

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

References

  1. State of oncological care in Russia in 2020. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 239 p. (In Russ.).
  2. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  3. Antoni S., Ferlay J., Soerjomataram I. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010
  4. Hamid A.R.A.H., Ridwan F.R., Parikesit D. et al. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol 2020;20(1):158. doi: 10.1186/s12894-020-00733-z
  5. Mir M.C., Marchioni M., Zargar H. et al. Nomogram predicting bladder cancer-specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium. Eur Urol Focus 2021;7(6):1347–54. doi: 10.1016/j.euf.2022.01.009
  6. Narain T.A., Mohan Tosh J., Gautam G. et al. Neoadjuvant therapy for cisplatin ineligible muscle invasive bladder cancer patients: a review of available evidence. Urology 2021;154:8–15. doi: 10.1016/j.urology.2021.03.010
  7. Lavnikova G.A. Histological method of quantitative evaluation of therapeutic tumor damage. Moscow: Metodicheskie Rekomendatsii, 1979. 13 p. (In Russ.).
  8. Pfister C., Gravis G., Fléchon A. et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol 2022;40(18):2013–22. doi: 10.1200/JCO.21.02051
  9. Pfister C., Gravis G., Fléchon A. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 2021;79(2):214–21. doi: 10.1016/j.eururo.2020.08.024
  10. Gladkov O.A., Zukov R.A., Matveev V.B. et al. Practical guidelines on drug treatment of bladder cancer. Zlokachestvennye opukholi: Prakticheskie rekommendatsii RUSSCO = Malignant Tumors: RUSSCO Practical Guidelines 2021;11(3s2):523–9. (In Russ.). doi: 10.18027/2224-5057-2021-11-3s2-32

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.